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Background: Febrile neutropenia is an oncologic emergency. The timing of antibiotics administration in patients with
febrile neutropenia may result in adverse outcomes. Our study aims to determine time-to- antibiotic administration in
patients with febrile neutropenia, and its relationship with length of hospital stay, intensive care unit monitoring, and
hospital mortality.
Methods: The study population was comprised of adult cancer patients with febrile neutropenia who were
hospitalized, at a tertiary care hospital, between January 2010 and December 2011. Using Multination Association of
Supportive Care in Cancer (MASCC) risk score, the study cohort was divided into high and low risk groups. A
multivariate regression analysis was performed to assess relationship between time-to- antibiotic administration and
various outcome variables.
Results: One hundred and five eligible patients with median age of 60 years (range: 18–89) and M:F of 43:62
were identified. Thirty-seven (35%) patients were in MASCC high risk group. Median time-to- antibiotic administration
was 2.5 hrs (range: 0.03-50) and median length of hospital stay was 6 days (range: 1–57). In the multivariate analysis
time-to- antibiotic administration (regression coefficient [RC]: 0.31 days [95% CI: 0.13-0.48]), known source of fever
(RC: 4.1 days [95% CI: 0.76-7.5]), and MASCC high risk group (RC: 4 days [95% CI: 1.1-7.0]) were significantly correlated
with longer hospital stay. Of 105 patients, 5 (4.7%) died & or required ICU monitoring. In multivariate analysis no
variables significantly correlated with mortality or ICU monitoring.
Conclusions: Our study revealed that delay in antibiotics administration has been associated with a longer hospital stay.
Keywords: Time to antibiotic, Febrile neutropenia, Length of stay, Outcome, Hospital mortalityBackground
Neutropenia is a major dose-limiting toxicity of cyto-
toxic agents that predisposes cancer patients to serious
infections [1-3]. Febrile neutropenia is considered to be
an oncologic emergency. The risk of life threatening bac-
terial infection increases when absolute neutrophil count
(ANC) drops below 0.5 × 109/l [1]. Although an infec-
tious source is identified in approximately 20 to 30% of
episodes of neutropenia and fever [3], empiric broad
spectrum antibiotics are the universal therapy for pa-
tients with febrile neutropenia. It involves the initiation
of antimicrobial therapy in patients with neutropenia, at
the time of the onset of fever, without establishing a* Correspondence: shahid.ahmed@saskcancer.ca
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reproduction in any medium, provided the ordefinitive diagnosis of microbial infection. A prolonged
time-to-antibiotic administration can result in adverse
outcomes in immune compromised patients. For in-
stance, the mortality rate, related to a febrile neutropenic
episode, has been variably reported between 2% and 20%
[2]. Therefore, it is crucial to recognized neutropenic
fever early and to commence broad spectrum empiric
antibiotics promptly in order to avoid sepsis syndrome
and possible death.
The American Society of Clinical Oncology and an inter-
national guideline panel of the Surviving Sepsis Campaign
recommend administering the first dose of empiric anti-
bacterial therapy as soon as possible after triage (within an
hour) to the patients with febrile neutropenia [4,5]. Several
studies assessed time-to- antibiotic administration in can-
cer patients presenting to emergency department (ED)
with febrile neutropenia [6-9]. However, limited evidenceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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antibiotic administration and length of hospital stay and
mortality in the era of modern anti-cancer therapy. For
instance, a national audit of 95 United Kingdom hospi-
tals reported that only 18 to 26% patients with neutro-
penic fever received initial empiric antibiotics within
the one hour “door-to-needle” target time frame with
mean mortality rate of 9% [8]. However, relationship be-
tween timing of antibiotic administration and mortality
or length of hospital stay was not assessed. In another
report median time from triage to antibiotic adminis-
tration, in patients with febrile neutropenia, was 5 hours
(range: 1.23–22.8 hours). However, delayed antibiotic
administration was not associated with increased risk of
death or increased length of hospital stay [9].
The current study aims to determine time-to- antibiotic
administration in adult cancer patients with febrile neu-
tropenia, a quality measure in cancer care; and to assess
the relationship between time-to- antibiotic administra-
tion and length of hospital stay, intensive care unit (ICU)
monitoring, and hospital mortality.Objectives
 To determine relationship between time-to- antibiotic
administration and hospital stay in adult cancer
patients with febrile neutropenia treated with
chemotherapy.
 To determine relationship between time-to- antibiotic
administration and ICU monitoring or hospital
mortality in adult cancer patients with febrile
neutropenia treated with chemotherapy.Methods
The study protocol was approved by the Biomedical
Ethics Board of University of Saskatchewan. The study
population was comprised of a cohort of consecutive
adult cancer patients with a diagnosis of febrile neutro-
penia who were hospitalized at a tertiary care hospital
(the Royal University Hospital) between January 2010
and December 2011. International Classification of Disease
(ICD) code was used to identify eligible patients. Diagnosis
was verified using Saskatchewan Cancer Registry data.
Medical records of all patients were reviewed retro-
spectively. Information was collected from the hospital
and cancer clinic record using a standard abstraction
sheet. Eligible patients were meeting the following criteria:
diagnosis of malignancy treated by chemotherapy that was
causative of or contributive to neutropenia (granulocyte
count < 500/μL or is expected to decrease to <500 cells/
microL over the next 48 hours), temperature greater than
38°C (measured orally and documented by the patient or
the medical/nursing staff ), and age greater ≥18 years. Onlythe first febrile episode occurring in a patient during the
study period was considered.
Patients were considered for inclusion if they were admit-
ted from the emergency department, or form an ambu-
latory care facility (the Saskatoon Cancer Center) to the
oncology ward. Time to antibiotic administration was
determined by time of ED registration until time of first
dose of antibiotic administration as indicated in the
medication administration record. For patients who
were admitted from the outpatient facility, time of initial
assessment by a nurse during clinic visit was used as an
indicator of initial awareness of patient being febrile. Pa-
tients with fever and neutropenia but no documented
malignancy were excluded.
The Multinational Association for Supportive Care in
Cancer (MASCC) validated risk index score was used to
stratify patients cohort into two risk groups [10,11]. (1)
high-risk group (MASCC score <21 points) and (2) low-
risk group (score ≥ 21 points). A secondary analysis
was performed in patients with solid tumors and with
hematological malignancies.
Statistical analysis
The data are reported as mean, medians, standard devi-
ation and ranges. For descriptive statistics Chi square test
and student t test were performed. Pearson correlation
was done to assess correlation between time-to- antibiotic
administration and length of hospital stay. Univariate re-
gression analysis was performed and following clinical var-
iables were examined to assess their association with the
duration of hospital stay: time-to- antibiotic administra-
tion, age, gender, comorbid illness, advanced disease, high
risk disease, hematological malignancy, ANC, blood urea
nitrogen (BUN), known source of fever, serum creatinine,
abnormal chest x-ray, and prophylactic use of filgrastim
and or antibiotic. A multiple linear regression model was
developed using variables that significantly correlated with
hospital stay (p ≤ 0.05 in univariate analysis), to identify
their individual contribution to length of hospital stay.
Binary logistic regression analysis was performed, to assess
relationship between various clinical variables and a com-
posite outcome of ‘Serious Adverse Events’ defined as
hospital mortality and or ICU admission (both variables
were not mutually exclusive) . Time to discharge was esti-
mated using Kaplan Meier method. Log Rank test was
done for comparison of time to discharge. All two-tailed
p-values <0.05 were considered to be significant. The stat-
istical analysis was performed using SPSS version 21 (SPSS
Inc. Chicago, IL).
Results
One hundred and five eligible patients with a median
age of 60 years (range: 18–89 years) and M:F of 43:62
were identified. Patients’ characteristics are described in
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high risk group and 68 (65%) were in MASCC low risk
group. Fifty two (49%) patients had a comorbid illness,
46 (44%) had a hematological malignancy, and 63 (60%)
had advanced disease. Patients in high risk group were
older, predominantly male, and had a significantly higher
prevalence of major medical illnesses (Table 1). Patients
with a hematological malignancy had more advanced
disease and more often received prophylactic filgrastim
and or antibiotics, during the last three months, com-
pared with patients with a solid tumor. Of 105 patients,
89 (85%) were presented to the ED and 16 (15%) were
hospitalized from the ambulatory clinic. Median time-
to- antibiotic administration was 2.5 hrs (0.03-50 hrs).
Nine percent patients received antibiotic treatment
within an hour of registration and 95% received antibi-
otics within 9.3 hrs. Eighty-eight (84%) patients were
treated with broad spectrum penicillin and 50 (47.6%)
patients received prophylactic filgrastim and or antibi-
otics over the past three months. Median length of stay
was 6 days (range: 1–57). A known source of infection was
identified in 23 (22%) patients (bacteremia, n = 12, positive
urine culture, n = 8, and chest infiltrates, n = 9). Pearson
correlation between time-to- antibiotic administration andTable 1 Characteristics of patients treated with febrile neutro
Clinical variables Total patients
N = 105 (%)
Median age yrs 60 (18–89)
Age over 65 36 (34)
Male 43 (41)
MASCC score 21 ± 2.5
Comorbid illness 52 (49)
Diabetes mellitus 12 (11)
Chronic renal failure 4 (4)
Hematological malignancies 46 (44)
Advanced disease 63 (60)
Prophylactic filgrastim & or antibiotics 50 (48)
Mean SBP mmHg 123 ± 22
Mean heart rate bpm 105 ± 20
Mean O2 saturation% 97 ± 2
Mean WBC 109/l 0.83 ± 2.8
Mean ANC 109/l 0.21 ± 0.23
Mean hemoglobin g/L 98 ± 21
Mean platelet count 109/l 136 ± 102
Mean serum sodium mEq/L 135 ± 3
Mean serum creatinine μmol/L 69 ± 36
Mean BUN mmol/L 5 ± 4.2
Median TAA hrs (range) 2.5 (0.03-50)
ANC = absolute neutrphil count, BUN = blood urea nitrogen, TAA = time to antibiotilength of stay was 0.26 (p = 0.008). In univariate analysis
time-to- antibiotic administration, MASCC high risk group,
known source of fever, and BUN were significantly cor-
related with length of stay (Table 2). In the multivariate
analysis time-to- antibiotic administration (regression
coefficient [RC]: 0.31 days [95% CI: 0.13-0.48]), known
source of fever (RC: 4.1 days [95% CI: 0.76-7.5]), and
MASCC high risk group (RC: 4 days [95% CI: 1.1-7.0])
were significantly correlated with length of stay. Of 105
patients, 5 (4.7%) patients died and or required ICU ad-
mission. Four died (3 patients with hematological malig-
nancies and 1 with solid tumors) and 2 required intensive
care monitoring. Overall 3 of 17 (17.6%) patients with
leukemia died or required ICU admission compared with
2 of 86 (2.3%) patients with non-leukemic malignancy
(p = 0.029). No significant difference was noted between
the two MASCC risk groups with respect to ICU admis-
sion or mortality. In univariate logistic regression analysis,
diagnosis of leukemia (odd ratio, 9.2, 95% CI: 1.4-60.1)
and bacteremia (odd ratio, 10.3, 95% CI: 1.4-74.1) were
significantly correlated hospital mortality and or ICU
admission (Table 3). On multivariate analysis no clinical
variable significantly correlated with ICU admission or
mortality.penia
High risk patients
N = 37 (%)
Low risk patients
N = 68 (%)
P value
66 (46–86) 55 (18–89) 0.058
22 (60) 14 (21) <0.001
21 (57) 22 (32) 0.01
18 ± 1.3 23 ± 1.5 0.15
32 (86) 20 (29) <0.001
8 (22) 4 (6) 0.02
3 (8) 1 (2) 0.12
19 (51) 27 (40) 0.17
24 (65) 39 (57) 0.29
17 (46) 33 (49) 0.48
120 ± 21 124 ± 23 0.71
101 ± 17 107 ± 21 0.97
97 ± 2 97 ± 2 0.76
1.5 ± 4.8 0.99 ± 0.69 0.056
0.21 ± 0.18 0.21 ± 0.25 0.08
97 ± 18 102 ± 23 0.20
127 ± 106 156 ± 98 0.004
134 ± 3 134 ± 4 0.60
99 ± 50 68 ± 16 <0.001
8.6 ± 5.3 4.7 ± 2.6 <0.001
3 (0.22-19) 2.5 (0.03-50) 0.16
cs administration, WBC = white blood cell, ± standard deviation.
Table 2 Relationship between duration of hospital stay






Time to antibiotic 0.26 0.10 0.008
MASCC high risk group 5.1 1.5 0.001
Blood urea nitrogen (BUN) 0.46 0.17 0.009
Known sources of fever 5.3 1.7 0.002
Hematological malignancy 2.1 1.5 0.16




Comorbid illness 1.8 1.5 0.24
Advanced stage 1.6 1.5 0.29
Absolute neutrophil count 3.2 3.2 0.32
Ambulatory care admission −1.5 2.0 0.46
Serum creatinine 0.01 0.02 0.66
Female gender −0.05 1.5 0.97
MASCC = the Multinational Association for Supportive Care in Cancer; A.
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Median duration of hospital stay in patients with
MASCC high risk group was 9 days (95% CI: 7.3-10.7)
compared with 6 days (95% CI: 5.3-6.7), in patients
with MASCC low risk score p < 0.001 (Figure 1A).
Patients with a known source of fever and documented
infection had median duration stay of 11 days (95% CI: 7.5-
14.5) compared with 6 days (95% CI: 5.5-6.5) in patients
with no documented source of fever, p = 0.004 (Figure 1B).
With respect to underlying malignancy, median dur-
ation of hospital stay in patients with hematological
malignancies was 8 days (95% CI: 6.7-9.2) compared
with 6 days (95% CI: 5.1-6.8) in patients with solid tu-
mors, p = 0.13. No significant difference in the lengthTable 3 Relationship between important clinical variables
and an adverse event in patients with febrile
neutropenia





Bacteremia 10 1.3-71.5 0.03




Age >65 yrs 3.5 0.55-22.6 0.18
Known source 2.5 0.39-15.9 0.33
Male gender 2.5 0.36-14.0 0.38




MASCC = the Multinational Association for Supportive Care in Cancer.of hospital stay was noted in patients with underlying
leukemia versus patients with non-leukemic hema-
tological malignancies.
Discussion
Our study demonstrated a positive relationship between
a delay in antibiotic administration and a longer hospital
stay. An hour delay in antibiotic administration was re-
sulted in approximately eight-hours increase in length of
hospital stay. The study also revealed a broad range of
times until antibiotic administration. Several guidelines
advocate initiation of empiric antimicrobial therapy
within 60 minutes of presentation in patients with febrile
neutropenia [4,5]. Although 95% patients received first
dose of empiric antibiotic therapy within 10 hours of
registration, only 9% received treatment within an hour.
Delay over 5 hrs was noted in 20% patients, with longest
being 50 hrs. The causal relationship between delay in
time-to-antibiotics and prolong hospital stay in our
study cohort remains speculative and may have been
due to slow recovery from underlying infection, persist-
ent fever and other complications. The common reasons
for delayed in assessment and antibiotic administration
reported in literature are: Antibiotics are prescribed by
doctors but their administration is delayed, prolonged
time to assessment by the junior staff, lack of awareness
of natural evolution of course of neutropenic sepsis, fail-
ure of the emergency department to stock the appropri-
ate antimicrobial therapy, and lack of a distinct protocol
for febrile neutropenia [8,9]. A significant decrease in
time-to- antibiotic administration has been demonstrated
when order sets were utilized to increase efficiency in anti-
biotic administration or when multiple ED initiatives were
taken to improve patients triage [12-14].
In addition to time-to- antibiotic administration, MASCC
high risk score and known sources of fever were correlated
with delay in hospital discharge. Patients in high risk
MASCC group had 4 days longer hospital stay com-
pared with low risk patients with MASCC score of ≥21.
The MASCC risk index score was developed with the
aim to identify patients with chemotherapy-induced fe-
brile neutropenia who are at low risk of serious medical
complication development [10,15]. In a multinational,
multicenter study of more than 1,100 patients with
febrile neutropenia, the Multinational Association for
Supportive Care in Cancer (MASCC) demonstrated
that certain characteristics such as old age, disease bur-
den, hypotension, dehydration, obstructive lung dis-
ease, hematological malignancy, and in-patients status
are associated with high risk of serious medical compli-
cations, and absence of such features can identify low-
risk patients. MASCC risk index has been validated and
has become part of the selection process of patients
who can safely be treated at home [15].
Figure 1 Duration of hospital stay for both low and high MASCC risk score. (A) Duration of hospital stay for both known and unknown
sources of infection (B).
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had 4 days longer length of stay compared with pa-
tients with no known source of fever. An infectioussource is indentified only in about one third of patients
with FN [1]. Bacteria are the most frequent infectious
causes of neutropenic fever and bacteremia is often the
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tified infections are thought to arise from the patient’s en-
dogenous flora. Immunosuppressive effects of anti-cancer
therapy, underlying cancer and its associated humoral or
cellular immune deficits predispose for specific types of
infections [1-3]. For example, T cell defects associated
with lymphoproliferative disorders result in an increased
risk of infection with intracellular pathogens, such as
Listeria monocytogenes. Although antibiotics are empir-
ically administered, it should always include appropriate
coverage for suspected organisms. The empiric antibiotic
therapy later can be modified once updated clinical and
microbiologic information are available.
Although one mmol/l rise in BUN resulted in approxi-
mately 11 hours longer length of stay, after adjustment for
MASCC score that takes dehydration into account, ele-
vated BUN was not independently correlated with prolong
hospital stay. Elevated BUN is a marker of hypovolemia
and has been identified as independent prognostic factors
for mortality and hospital stay in critically ill patients [16].
Patients with cancer who are undergoing active treatment
can have reduced oral intake and are at risk of dehydra-
tion due to anorexia, early satiety, nausea and vomiting,
mucositis, dysphagia, delayed gastric emptying, and diar-
rhea. Hence, adequate hydration is crucial in patients with
febrile neutropenia to avoid renal function impairment,
longer stay and other complications.
The mortality rate of the study cohort was 3.8%. Patients
with prolonged neutropenia, major comorbid illness and
organ dysfunction are at risk of serious complications
[1,5,17]. A very high mortality rate, up to 90%, had been
reported in patients with febrile neutropenia before the
empiric use of antibiotic [18]. Kuderer and others, using
longitudinal discharge database derived from 115 US
hospitals, studied more than 4,000 adult cancer patients
with febrile neutropenia who were hospitalized between
1995–2000, and reported in-hospital mortality of 9.5% [2].
Underlying cancer, major comorbid illness, and infectious
complications such as pneumonia and sepsis were signi-
ficantly associated with increased mortality. Patients who
are critically ill have poor outcomes and high hospital
mortality. For example, a French study involving neutro-
penic patients with severe sepsis or septic shock, treated
between 1998 and 2008, demonstrated hospital mortality
rate of 50% [19]. In our study patients with underlying
leukemia or bacteremia were at high risk of hospital mor-
tality and or ICU admission, however, no factor independ-
ently correlated with an adverse outcome after adjustment
for other variables. Likewise, time-to- antibiotic adminis-
tration did not correlate with ICU admission or mortality.
It is plausible that due to small number of serious adverse
events, our study was not adequately powered to detect
significant association between ICU admission or hospital
mortality and various prognostic variables.The current study is one of the very few studies that
evaluated relationship between timing of antibiotic and
duration of hospital stay and other important outcomes
using a validated risk score. One of the limitations of the
present study is that it did not evaluate potential reasons
for delayed in assessment and antibiotic administration.
Furthermore, patients who were treated at the rural
hospitals were excluded; hence, the results may not be
generalizable to the rural cancer population. Although
most patients developed fever at home, information on
the time when fever was first noted by the patients was
not available in most cases and registration time was
used as surrogate of onset of fever to eliminate infor-
mation bias.
Conclusions
This retrospective cohort study revealed a positive rela-
tionship between time-to-antibiotic and prolonged
hospital stay. Only one in ten patients received antibiotic
within an hour of registration. In addition, high risk
patients or patients with known source of infection had
longer hospital stay. The study with its limitation did
not reveal association between delay in antibiotic admin-
istration and hospital mortality or ICU admission. We
believe that patients and health care staff education, es-
tablishment of bench mark time, and access to standard
treatment protocol in ED can potentially be helpful for
prompt triage of patients with febrile neutropenia and
timely antibiotic administration to shorten hospital stay
and avoid other complications.
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